GLP1R and tricuspid valve insufficiency: Agents like finerenone and Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are gaining traction for their cardio–renal–metabolic benefits [7,8], while transcatheter therapies for tricuspid regurgitation (TR) are shifting TR from a neglected finding to an actionable contributor to disease progression [9].